Novavax, Inc. Reports on Progress with RSV Vaccine at New International Conference on Modern Vaccines
Published: Jul 05, 2012
ROCKVILLE, Md., July 5, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported this week that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, reviewed recent preclinical and clinical findings from the company's respiratory syncytial virus (RSV) vaccine development program at the first Modern Vaccines Adjuvants and Delivery Systems conference in Copenhagen, Denmark. He reported that the findings from the recent Phase I trial were consistent with the preclinical results in relevant animal models, which indicated that the Novavax Fusion (F) protein nanoparticle RSV vaccine candidate was generally well-tolerated, highly immunogenic and produced functional antibodies that neutralized RSV. There is currently no vaccine available to prevent RSV, which is the leading cause of bronchiolitis and pneumonia in infants under one year of age and a leading cause of pneumonia in older adults.